{
    "nctId": "NCT00289263",
    "briefTitle": "Maintenance Chemotherapy in Metastatic Breast Cancer",
    "officialTitle": "Maintenance Paclitaxel Vs Control After Anthracycline/Paclitaxel Combined First-Line Chemotherapy in Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 524,
    "primaryOutcomeMeasure": "Time to disease progression with maintenance paclitaxel versus observation",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent.\n* Patients with metastatic breast cancer in response or stable disease after six to eight courses of first line induction chemotherapy treatment\n* Measurable and/or evaluable disease\n* Performance status ECOG 0, 1, 2.\n* Normal cardiac function, confirmed by left ventricular ejection fraction (LVEF).\n\nExclusion Criteria:\n\n* Presence of peripheral neuropathy \\> grade 2 by NCI Common Toxicity Criteria (NCI-CTC) following induction chemotherapy\n* Adjuvant taxane-based therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}